PMID- 12904127
OWN - NLM
STAT- MEDLINE
DCOM- 20030912
LR  - 20191210
IS  - 1474-0338 (Print)
IS  - 1474-0338 (Linking)
VI  - 2
IP  - 1
DP  - 2003 Jan
TI  - Safety of low molecular weight heparins in the treatment of venous 
      thromboembolism.
PG  - 87-94
AB  - Low molecular weight heparins (LMWHs) are commonly employed as a substitute for 
      unfractionated heparin (UFH) in the treatment of venous thromboembolic events. 
      Despite their higher cost, the preferential use of LMWHs seemed justified 
      initially as, based on the results of earlier meta-analyses, these compounds were 
      deemed to be more effective and safer than UFH. Although, in this respect, their 
      purported superiority over UFH could not be confirmed by subsequent large, 
      randomised trials and updated meta-analyses, other peculiar features of LMWHs 
      were highlighted, favouring their preferential utilisation in patients with 
      venous thromboembolism. Among these, the possibility of once-daily administration 
      on an out-patient basis, the lower incidence of Type II heparin-induced 
      thrombocytopenia and the lower likelihood of osteoporosis after prolonged 
      treatment periods, appear to be especially prominent. This review attempts to 
      evaluate the available evidence focusing on the safety of LMWHs for the treatment 
      of venous thromboembolism and the current therapeutic options and potential 
      advantages of LMWHs, either in general or in selected patient populations.
FAU - Bernardi, Enrico
AU  - Bernardi E
AD  - Pronto Soccorso, Azienda Ospedaliera di Padova, Via Giustiniani, n.1, 35128 - 
      Padova, Italy. enriberni@hotmail.com
FAU - Prandoni, Paolo
AU  - Prandoni P
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Drug Compounding
MH  - Hemorrhage/chemically induced/complications
MH  - Heparin, Low-Molecular-Weight/*adverse effects/therapeutic use
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Safety
MH  - Thrombocytopenia/*chemically induced
MH  - Treatment Outcome
MH  - Venous Thrombosis/complications/*drug therapy
RF  - 51
EDAT- 2003/08/09 05:00
MHDA- 2003/09/13 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2003/09/13 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
AID - 10.1517/14740338.2.1.87 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2003 Jan;2(1):87-94. doi: 10.1517/14740338.2.1.87.